Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CUVL

Clinuvel Pharmaceuticals Ltd ADR

6.82

Aug 03 • 4:00 AM ET +0.33 (5.08%)

Healthcare Biotechnology Australia Small NASD

Scroll to Statements

Index	-
Market Cap	343.80M
Enterprise Value	188.64M
Income	20.86M
Sales	61.86M
Book/sh	3.31
Cash/sh	3.08
Dividend Est.	0.04 (0.60%)
Dividend TTM	0.03 (0.48%)
Dividend Ex-Date	-
Dividend Gr. 3/5Y	14.47% 24.57%
Payout	5.58%
Employees	-
IPO	Jul 02, 2004

P/E	16.51
Forward P/E	13.21
PEG	0.93
P/S	5.56
P/B	2.06
P/C	2.21
P/FCF	13.57
EV/EBITDA	7.55
EV/Sales	3.05
Quick Ratio	14.17
Current Ratio	14.64
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	0.41
EPS next Y	0.52
EPS next Q	0.32
EPS this Y	5.59%
EPS next Y	4.35%
EPS next 5Y	14.26%
EPS past 3/5Y	15.14% 17.96%
Sales past 3/5Y	8.89% 23.03%
EPS Y/Y TTM	-18.45%
Sales Y/Y TTM	2.48%
EPS Q/Q	-26.96%
Sales Q/Q	2.70%
Earnings	Feb 25 AMC
EPS/Sales Surpr.	-25.90% 2.16%

Insider Own	-
Insider Trans	-
Inst Own	0.01%
Inst Trans	-3.99%
ROA	12.79%
ROE	13.88%
ROIC	12.56%
Gross Margin	63.62%
Oper. Margin	39.27%
Profit Margin	33.72%
SMA20	-3.74%
SMA50	-0.99%
SMA200	-7.79%
Trades

Shs Outstand	50.18M
Shs Float	37.77M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	9.00 -24.22%
52W Low	5.98 14.05%
Volatility	8.01% 4.81%
ATR (14)	0.41
RSI (14)	46.38
Beta	0.86
Rel Volume	0.03
Avg Volume	4.15K
Volume	6

Perf Week	-2.71%
Perf Month	-7.21%
Perf Quarter	1.79%
Perf Half Y	-10.97%
Perf YTD	-19.58%
Perf Year	-13.67%
Perf 3Y	-40.70%
Perf 5Y	-65.86%
Perf 10Y	78.07%
Recom	1.20
Target Price	16.52
Prev Close	6.49
Price	6.82
Change	5.08%

Jul-23-26 12:10AM

CLINUVEL implements strategic reorganisation to refocus on U.S. markets

(GlobeNewswire)

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

M.D.Dr. Philippe Jacques Wolgen M.B.A.

Chief Financial OfficerMr. Peter Vaughan

Chief Operations OfficerMr. Lachlan Hay

M.Sc.Dr. Dennis J. Wright BPharm

Head of Australian Operations & Investor RelationsMr. Malcolm Bull

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CUVL

Clinuvel Pharmaceuticals Ltd ADR

Upgrade your Finviz experience